Michael Schmitz
Stock Analyst at Guggenheim
(3.56)
Main Sectors:
Top Industries:
15 Stocks
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
MRUS Merus | Downgrades: Neutral | 109 97 | 94.29 | 2.87% | 3 | Sep 30, 2025 | |
GMAB Genmab | Upgrades: Buy | 43 | 33.56 | 28.13% | 1 | Sep 24, 2025 | |
EXEL Exelixis | Reiterates: Buy | 45 45 | 40.09 | 12.25% | 1 | Jul 29, 2025 | |
RVMD Revolution Medicines | Maintains: Strong Buy | 72 82 | 46.71 | 75.55% | 2 | Oct 28, 2024 | |
BPMC Blueprint Medicines | Maintains: Strong Buy | 130 138 | n/a | n/a | 8 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 40 | 9.61 | 316.23% | 1 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 35 | n/a | n/a | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 15 | n/a | n/a | 1 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Mar 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Mar 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 27 | n/a | n/a | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 61 | n/a | n/a | 3 | Jan 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 85 | n/a | n/a | 1 | Dec 19, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 80 | n/a | n/a | 2 | Dec 19, 2016 |